ISBN: First Author / Trial name n. Country Recruitment HFRE F or both Start s inpat ient QoL Outcomes: Mort/ Hosp Meds Length (months ) Last measure (months ) Face-to- face meeting s III-IV inine Del sindaco 200791 173 Italy Hospitalised, aged 70 or more, and discharged home. NYHA III-IV and required IV diuretics both On dc Deaths, Admissions OPTIMAL trial 208 Sweden Patients hospitalised with heart failure with NYHA II-IV and LV systolic dysfunction both On dc Nottingh am Health Profile Death, Admissions Px flex 6- Ave 37 mean attend PRICE trial Atienza 153 Spain Cardiology ward with diagnosis of primary HF both Yes MLWHF Q Deaths, Admissions Low risk (stable HF) Long interventions 160 Sweden Patients recruited from PC with CHF and LVEF<50% HFRE F No SF-36* Death, Admissions HICMan trial 197 Germany Patients recruited from PC with hospital admission with HF in last two years, objective CHF and LVEF<45% HFRE F KCCQ Death, Admissions 153 Sweden Recruited from PC, NYHA II-IV both No SF-36* Death Px 12 12 mean Northstar trial 921 Denmark Stable CHF on optimal meds, HFRE F No MLWHF Death, Admissions Px, Adv. effects 83 UK Elderly patients recruited from inpatient or outpatient with diagnosis CHF both No SF-36* MLWHF Death, Admissions Adher- ence *reported incompletely, therefore not included in analysis NR: measured but not reported Px: prescription of ACEi+/beta-blocker+/MRA dc: on discahrge Referral and approach to care Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Table 100: Papers according to population risk: risk strata and background rate of admission (IQR 0.6-1.6, values outside IQR are highlighted) Risk strata (proportions are estimates) First Author / Trial name New dxa ADHFb Severec Req. 